Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development-Reference-Cited by-同舟云学术

Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development

Published:2018-01-08 Issue:3 Volume:46 Page:237-247
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Zheng Jim,Xin Yan,Zhang Jingyu,Subramanian Raju,Murray Bernard P.,Whitney J. Andrew,Warr Matthew R.,Ling John,Moorehead Lisa,Kwan Ellen,Hemenway Jeffrey,Smith Bill J.,Silverman Jeffrey A.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference63 articles.

1. Cyanide Trapping of Iminium Ion Reactive Intermediates Followed by Detection and Structure Identification Using Liquid Chromatography−Tandem Mass Spectrometry (LC-MS/MS)

2. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

3. The Jak1/Jak2 inhibitor momelotinib inhibits Alk2, decreases hepcidin production and ameliorates anemia of chronic disease (ACD) in rodents;Asshoff;Blood,2015

4. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity;European Journal of Medicinal Chemistry;2024-12

2. Crosstalk and Prospects of TBK1 in Inflammation;Immunological Investigations;2024-08-28

3. Momelotinib: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-08

4. Bioactivation and reactivity research advances – 2023 year in review;Drug Metabolism Reviews;2024-07-17

5. Momelotinib – a promising advancement in the management of myelofibrosis in adults with anemia;Frontiers in Oncology;2024-06-25